Back to Search Results
Image Place holder

Brandon Manley, MD

★★★★★
★★★★★
4.9 (244 ratings)
Specialty: Urology
Program: Genitourinary Oncology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Adrenal Carcinoma, Bladder Cancer, Kidney (Renal Cell) Cancer, Prostate Cancer, Testicular Cancer

Dr. Manley earned his MD degree at Temple University, Philadelphia, Pennsylvania. He completed a Urologic Residency at Washington University, St. Louis, Missouri and a Urologic Oncology Fellowship at Memorial Sloan Kettering Cancer Center in New York. Dr. Manley’s clinical practice centers on malignant tumors of the prostate, kidneys, bladder and testis. Using a variety of surgical techniques, including robotic and open surgery, he supports the comprehensive treatment plans for patients with genitourinary cancers at Moffitt.


Education & Training

Fellowship:

  • Memorial Sloan Cancer Center - Urologic Oncology

Residency:

  • Washington University - Urologic

Medical School:

  • Temple University - MD
Participating Trials

CLINICAL TRIAL 21266
Gut Metabolome-Can it be Developed As A Biomarker of Response to Immunotherapy in Metastatic Renal Cell Cancer
Condition: Genitourinary
Intervention:
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Fink AKC, DeRenzis AC, Awasthi S, Jahan N, Johnstone PAS, Pow-Sang J, Torres-Roca J, Grass D, Fernandez D, Naghavi A, Tan S, Manley B, Li R, Poch M, Yu A, Little N, Bass E, Ercole CE, Katsoulakis E, Burri R, Smith R, Stanley NB, Vadaparampil ST, Yamoah K. Identifying and overcoming barriers to participation of minority populations in clinical trials: Lessons learned from the VanDAAM study. Cancer Med. 2023 Jan.12(2):1869-1877. Pubmedid: 35796421. Pmcid: PMC9883445.
  • Soupir AC, Tian Y, Stewart PA, Nunez-Lopez YO, Manley BJ, Pellini B, Bloomer AM, Zhang J, Mo Q, Marchion DC, Liu M, Koomen JM, Siegel EM, Wang L. Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer. Int J Mol Sci. 2023 Jan.24(3). Pubmedid: 36768152. Pmcid: PMC9916336.
  • Mason NT, Joshi VB, Adashek JJ, Kim Y, Shah SS, Schneider AM, Chadha J, Jim HSL, Byrne MM, Gilbert SM, Manley BJ, Spiess PE, Chahoud J. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma. Eur Urol Oncol. 2023 Feb. Pubmedid: 36797084.
  • Kumar NB, Bahl S, Dhillon J, Poch M, Manley B, Li R, Schell M, Powsang J. Challenges to Recruiting Men on Active Surveillance for Prostate Cancer in Clinical Chemoprevention Trials. Cancers (Basel). 2023 Feb.15(4). Pubmedid: 36831597. Pmcid: PMC9954186.
  • Chang A, Chakiryan NH, Du D, Stewart PA, Zhang Y, Tian Y, Soupir AC, Bowers K, Fang B, Morganti A, Teer JK, Kim Y, Spiess PE, Chahoud J, Noble JD, Putney RM, Berglund AE, Robinson TJ, Koomen JM, Wang L, Manley BJ. Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma. Eur Urol. 2022 Oct.82(4):354-362. Pubmedid: 35718636.
  • Rappold PM, Vuong L, Leibold J, Chakiryan NH, Curry M, Kuo F, Sabio E, Jiang H, Nixon BG, Liu M, Berglund AE, Silagy AW, Mascareno A, Golkaram M, Marker M, Reising A, Savchenko A, Millholland JM, Chen YB, Russo P, Coleman J, Reznik E, Manley BJ, Ostrovnaya I, Makarov V, DiNatale RG, Blum KA, Ma X, Chowell D, Li MO, Solit DB, Lowe SW, Chan TA, Motzer RJ, Voss MH, Hakimi AA. A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. Cancer Discov. 2022 Oct.12(10):2308-2329. Pubmedid: 35758895. Pmcid: PMC9720541.
  • Rose KM, Narang G, Rosen G, Labatte C, Dumitrascu C, Campagna J, Yu A, Manley BJ, Spiess PE, Li R, Adibi M, Murray KS, Sexton WJ, Humphreys MR. Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study. BJU Int. 2022 Oct. Pubmedid: 36285629.
  • Shaw TI, Zhao B, Li Y, Wang H, Wang L, Manley B, Stewart PA, Karolak A. Multi-omics approach to identifying isoform variants as therapeutic targets in cancer patients. Front Oncol. 2022 Nov.12:1051487. Pubmedid: 36505834. Pmcid: PMC9730332.
  • Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, Nguyen J, Fan W, Cheng CH, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, Mulé J, Du D, Yoder SJ, Berglund A, Teer JK, Manley BJ. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2022 May.8(3):784-793. Pubmedid: 33994165.
  • Chakiryan NH, Gore LR, Reich RR, Dunn RL, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Manley BJ, Sexton WJ, Hollenbeck BK, Gilbert SM. Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2022 May.5(5):e2212347. Pubmedid: 35576003. Pmcid: PMC9112069.
  • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Li R, Sexton W, Manley BJ, Gilbert SM. Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder. Urol Oncol. 2022 Mar.40(3):107.e11-107.e17. Pubmedid: 34426068.
  • Ferrall-Fairbanks MC, Chakiryan N, Chobrutskiy BI, Kim Y, Teer JK, Berglund A, Mulé JJ, Fournier M, Siegel EM, Dhillon J, Falasiri SSA, Arturo JF, Katende EN, Blanck G, Manley BJ, Altrock PM. Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma. Cancer Res. 2022 Mar.82(5):929-942. Pubmedid: 35031572. Pmcid: PMC8898280.
  • Rose KM, Huelster HL, Roberts EC, Manley BJ, Gilbert SM, Sexton WJ. Contemporary Management of Chylous Ascites after Retroperitoneal Surgery: Development of an Evidence-Based Treatment Algorithm. J Urol. 2022 Jul.208(1):53-61. Pubmedid: 35212572.
  • Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2022 Jan.20(1):67-81. Pubmedid: 34991070.
  • Patel SY, Trona N, Alford B, Laborde JM, Kim Y, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Preoperative immunonutrition and carbohydrate loading associated with improved bowel function after radical cystectomy. Nutr Clin Pract. 2022 Feb.37(1):176-182. Pubmedid: 33900647.
  • Awasthi S, Grass GD, Torres-Roca J, Johnstone PAS, Pow-Sang J, Dhillon J, Park J, Rounbehler RJ, Davicioni E, Hakansson A, Liu Y, Fink AK, DeRenzis A, Creed JH, Poch M, Li R, Manley B, Fernandez D, Naghavi A, Gage K, Lu-Yao G, Katsoulakis E, Burri RJ, Leone A, Ercole CE, Palmer JD, Vapiwala N, Deville C, Rebbeck TR, Dicker AP, Kelly W, Yamoah K. Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease. J Natl Cancer Inst. 2022 Dec.114(12):1656-1664. Pubmedid: 36053178. Pmcid: PMC9745424.
  • Kumar NB, Hogue S, Pow-Sang J, Poch M, Manley BJ, Li R, Dhillon J, Yu A, Byrd DA. Effects of Green Tea Catechins on Prostate Cancer Chemoprevention: The Role of the Gut Microbiome. Cancers (Basel). 2022 Aug.14(16). Pubmedid: 36010981. Pmcid: PMC9406482.
  • Zhang Y, Kumar P, Adashek JJ, Skelton WP, Li J, Vosoughi A, Chahoud J, Manley BJ, Spiess PE. Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma. Cells. 2022 Aug.11(16). Pubmedid: 36010582. Pmcid: PMC9406439.
  • Chadha J, Adashek JJ, Jim H, Kim Y, Semaan A, Chakiryan NH, Safa H, Hajiran A, Sexton W, Gilbert SM, Manley BJ, Spiess PE, Chahoud J. Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Miss. Clin Genitourin Cancer. 2022 Apr.20(2):e158-e165. Pubmedid: 34974985.
  • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Poch M, Manley BJ, Li R, Sexton W, Gilbert SM. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. J Urol. 2021 Oct.206(4):924-932. Pubmedid: 34032503.
  • Imbulana DI, Owen LS, Prentice TM, Davis PG, Manley BJ. Deferred Consent in Neonatal Clinical Research: Why, When, How?. Paediatr Drugs. 2021 Nov.23(6):565-573. Pubmedid: 34651279.
  • Huang J, Soupir AC, Schlick BD, Teng M, Sahin IH, Permuth JB, Siegel EM, Manley BJ, Pellini B, Wang L. Cancer Detection and Classification by CpG Island Hypermethylation Signatures in Plasma Cell-Free DNA. Cancers (Basel). 2021 Nov.13(22). Pubmedid: 34830765. Pmcid: PMC8616264.
  • Rubino S, Kim Y, Zhou J, Dhillon J, Li R, Spiess P, Poch M, Manley BJ, Pow-Sang J, Gilbert S, Sexton W, Zhang J. Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. World J Urol. 2021 May.39(5):1539-1547. Pubmedid: 32656671.
  • Safa H, Tamil M, Spiess PE, Manley B, Pow-Sang J, Gilbert S, Safa F, Gonzalez BD, Oswald LB, Semaan A, Diab A, Chahoud J. Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review. J Natl Cancer Inst. 2021 May.113(5):532-542. Pubmedid: 33146385. Pmcid: PMC8096374.
  • Patel SY, Kubal TE, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Boulware D, Poch MA. Prevalence of Preoperative Iron Deficiency Anemia: A Case Series Among Patients Undergoing Radical Cystectomy. A A Pract. 2021 May.15(5):e01477. Pubmedid: 33999012.
  • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Sexton W, Gilbert SM, Manley BJ. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2021 May.4(5):e2111329. Pubmedid: 34032854. Pmcid: PMC8150693.
  • Zaman S, Hajiran A, Coba GA, Robinson T, Madanayake TW, Segarra DT, Chobrutskiy BI, Boyle TA, Zhou JM, Kim Y, Mulé JJ, Teer JK, Manley BJ. Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy. Eur Urol Focus. 2021 Mar.7(2):373-380. Pubmedid: 31901438. Pmcid: PMC7771328.
  • Yuan Z, Fernandez D, Dhillon J, Abraham-Miranda J, Awasthi S, Kim Y, Zhang J, Jain R, Serna A, Pow-Sang JM, Poch M, Li R, Manley B, Fink A, Naghavi A, Torres-Roca JF, Grass GD, Kim S, Latifi K, Hunt D, Johnstone PAS, Yamoah K. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. Prostate Cancer P D. 2021 Mar.24(1):140-149. Pubmedid: 32651467. Pmcid: PMC7882397.
  • Hajiran A, Azizi M, Aydin AM, Chakiryan NH, Peyton CC, Boulware DC, Manley BJ, Gilbert SM, Sexton WJ. Retroperitoneal Lymph Node Dissection Versus Surveillance for Adult Early Stage Pure Testicular Teratoma: A Nationwide Analysis. Ann Surg Oncol. 2021 Jul.28(7):3648-3655. Pubmedid: 33689081. Pmcid: PMC9801512.
  • Parikh N, Keshishian E, Manley B, Grass GD, Torres-Roca J, Boulware D, Feuerlein S, Pow-Sang JM, Bagla S, Yamoah K, Bhatia S. Effectiveness and Safety of Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms from Benign Prostatic Hyperplasia in Men with Concurrent Localized Prostate Cancer. J Vasc Interv Radiol. 2021 Jul.32(7):1053-1061. Pubmedid: 33794373.
  • Chakiryan NH, Kimmel GJ, Kim Y, Johnson JO, Clark N, Hajiran A, Chang A, Aydin AM, Zemp L, Katende E, Chahoud J, Ferrall-Fairbanks MC, Spiess PE, Francis N, Fournier M, Dhillon J, Park JY, Wang L, Mulé JJ, Altrock PM, Manley BJ. Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2021 Jul.13(15). Pubmedid: 34359645. Pmcid: PMC8345222.
  • Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. J Urol. 2021 Jan.205(1):100-108. Pubmedid: 32783489. Pmcid: PMC7864376.
  • Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Reply By Authors. J Urol. 2021 Jan.205(1):108. Pubmedid: 33095102.
  • Mazin A, Hawkins SH, Stringfield O, Dhillon J, Manley BJ, Jeong DK, Raghunand N. Identification of sarcomatoid differentiation in renal cell carcinoma by machine learning on multiparametric MRI. Sci Rep. 2021 Feb.11(1):3785. Pubmedid: 33589715. Pmcid: PMC7884398.
  • Adashek JJ, Zhang Y, Skelton WP, Bilotta A, Chahoud J, Zemp L, Li J, Dhillon J, Manley B, Spiess PE. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?. Front Oncol. 2021 Feb.10:627025. Pubmedid: 33643921. Pmcid: PMC7902859.
  • Hajiran A, Chakiryan N, Aydin AM, Zemp L, Nguyen J, Laborde JM, Chahoud J, Spiess PE, Zaman S, Falasiri S, Fournier M, Teer JK, Dhillon J, McCarthy S, Moran-Segura C, Katende EN, Sexton WJ, Koomen JM, Mulé J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clin Exp Immunol. 2021 Apr.204(1):96-106. Pubmedid: 33346915. Pmcid: PMC7944355.
  • Chakiryan NH, Kimmel GJ, Kim Y, Hajiran A, Aydin AM, Zemp L, Katende E, Nguyen J, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, El-Kenawi A, Mulé J, Altrock PM, Manley BJ. Spatial clustering of CD68+ tumor associated macrophages with tumor cells is associated with worse overall survival in metastatic clear cell renal cell carcinoma. PLoS One. 2021 Apr.16(4):e0245415. Pubmedid: 33882057. Pmcid: PMC8059840.
  • Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Canc Ne. 2020 Sep.18(9):1160-1170. Pubmedid: 32886895.
  • Aydin AM, Gage K, Dhillon J, Cheriyan SK, Poch MA, Manley BJ, Li R, Sexton WJ, Spiess PE, Gilbert SM, Pow-Sang JM. Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility. Int J Urol. 2020 Oct.27(10):882-889. Pubmedid: 32767444.
  • Berglund A, Amankwah EK, Kim YC, Spiess PE, Sexton WJ, Manley B, Park HY, Wang L, Chahoud J, Chakrabarti R, Yeo CD, Luu HN, Pietro GD, Parker A, Park JY. Influence of gene expression on survival of clear cell renal cell carcinoma. Cancer Med. 2020 Nov.9(22):8662-8675. Pubmedid: 32986937. Pmcid: PMC7666730.
  • Parikh N, Keshishian E, Sharma A, Roca M, Manley B, Poch M, Grass GD, Torres-Roca J, Boulware D, Johnstone P, Montejo M, Smith J, Pow-Sang J, Yamoah K. Prostatic Artery Embolization Is Safe and Effective for Medically Recalcitrant Radiation-Induced Prostatitis. Adv Radiat Oncol. 2020 Apr.
  • Parikh N, Keshishian E, Sharma A, Roca M, Manley B, Poch M, Grass GD, Torres-Roca J, Boulware D, Johnstone P, Montejo M, Smith J, Pow-Sang J, Yamoah K. Prostatic Artery Embolization Is Safe and Effective for Medically Recalcitrant Radiation-Induced Prostatitis. Adv Radiat Oncol. 2020 Apr.5(5):905-909. Pubmedid: 33083652. Pmcid: PMC7557125.
  • Casuscelli J, Becerra MF, Seier K, Manley BJ, Benfante N, Redzematovic A, Stief CG, Hsieh JJ, Tickoo SK, Reuter VE, Coleman JA, Russo P, Ostrovnaya I, Hakimi AA. Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. Clin Genitourin Cancer. 2019 Oct.17(5):373-379.e4. Pubmedid: 31326335. Pmcid: PMC6790280.
  • Silagy AW, Sanchez A, Manley BJ, Bensalah K, Bex A, Karam JA, Ljungberg B, Shuch B, Hakimi AA. Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management. Eur Urol Focus. 2019 Nov.5(6):949-957. Pubmedid: 31040082. Pmcid: PMC6815690.
  • Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, Agarwal N, Bhayani S, Choueiri TK, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA, Hammond LJ, Zuccarino-Catania G. NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. J Natl Compr Canc Ne. 2019 Nov.17(11):1278-1285. Pubmedid: 31693980.
  • Casuscelli J, Becerra MF, Manley BJ, Zabor EC, Reznik E, Redzematovic A, Arcila ME, Tennenbaum DM, Ghanaat M, Kashan M, Stief CG, Carlo M, Voss MH, Feldman DR, Motzer RJ, Chen Y, Reuter VE, Coleman JA, Russo P, Hsieh JJ, Hakimi AA. Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. Eur Urol Focus. 2019 Jul.5(4):642-649. Pubmedid: 28951115. Pmcid: PMC5984188.
  • Manley BJ, Reznik E, Ghanaat M, Kashan M, Becerra MF, Casuscelli J, Tennenbaum D, Redzematovic A, Carlo MI, Sato Y, Arcila M, Voss MH, Feldman DR, Motzer RJ, Russo P, Coleman J, Hsieh JJ, Hakimi AA. Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. Urol Oncol. 2019 Jan.37(1):12-17. Pubmedid: 29132830. Pmcid: PMC5984192.
  • Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ, Fishman M, Zhang J, Gilbert SM. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Oncol. 2018 Nov.4(11):1535-1542. Pubmedid: 30178038. Pmcid: PMC6248089.
  • Becerra MF, Reznik E, Redzematovic A, Tennenbaum DM, Kashan M, Ghanaat M, Casuscelli J, Manley B, Jonsson P, DiNatale RG, Blum KA, Durack JC, Solomon SB, Arcila ME, Bourque C, Socci N, Carlo MI, Lee CH, Voss MH, Feldman DR, Motzer RJ, Coleman JA, Russo P, Cheng EH, Hakimi AA, Hsieh JJ. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. Eur Urol Focus. 2018 Dec.4(6):986-994. Pubmedid: 29066084. Pmcid: PMC5910293.
  • Kumar NB, Dickinson SI, Schell MJ, Manley BJ, Poch MA, Pow-Sang J. Green tea extract for prevention of prostate cancer progression in patients on active surveillance. Oncotarget. 2018 Dec.9(102):37798-37806. Pubmedid: 30701033. Pmcid: PMC6340872.
  • Kashan M, Ghanaat M, Hötker AM, Duzgol C, Sanchez A, DiNatale RG, Blum KA, Becerra M, Manley BJ, Casuscelli J, Chiok M, Coleman JA, Russo P, Tickoo SK, Akin O, Hakimi AA. Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging. J Urol. 2018 Aug.200(2):275-282. Pubmedid: 29496470. Pmcid: PMC6050111.
  • Manley BJ, Kim EH, Vetter JM, Potretzke AM, Strope SA. Validation of preoperative variables and stratification of patients to help predict benefit of cytoreductive nephrectomy in the targeted therapy ERA. Int Braz J Urol. 2017 May.43(3):432-439. Pubmedid: 28128914. Pmcid: PMC5462133.
  • Casuscelli J, Weinhold N, Gundem G, Wang L, Zabor EC, Drill E, Wang PI, Nanjangud GJ, Redzematovic A, Nargund AM, Manley BJ, Arcila ME, Donin NM, Cheville JC, Thompson RH, Pantuck AJ, Russo P, Cheng EH, Lee W, Tickoo SK, Ostrovnaya I, Creighton CJ, Papaemmanuil E, Seshan VE, Hakimi AA, Hsieh JJ. Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. JCI Insight. 2017 Jun.2(12). Pubmedid: 28614790. Pmcid: PMC5470887.
  • Manley BJ, Tennenbaum DM, Vertosick EA, Hsieh JJ, Sjoberg DD, Assel M, Benfante NE, Strope SA, Kim E, Casuscelli J, Becerra MF, Coleman JA, Hakimi AA, Russo P. The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models. Urol Oncol. 2017 Jan.35(1):35.e1-35.e5. Pubmedid: 27567689. Pmcid: PMC5154851.
  • Dong Y, Manley BJ, Becerra MF, Redzematovic A, Casuscelli J, Tennenbaum DM, Reznik E, Han S, Benfante N, Chen YB, Arcila ME, Aras O, Voss MH, Feldman DR, Motzer RJ, Fabbri N, Healey JH, Boland PJ, Chawla M, Durack JC, Lee CH, Coleman JA, Russo P, Hakimi AA, Cheng EH, Hsieh JJ. Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. Eur Urol Focus. 2017 Dec.3(6):590-598. Pubmedid: 28753786. Pmcid: PMC5608640.
  • Tennenbaum DM, Manley BJ, Zabor E, Becerra MF, Carlo MI, Casuscelli J, Redzematovic A, Khan N, Arcila ME, Voss MH, Feldman DR, Motzer RJ, Benfante NE, Coleman JA, Russo P, Hsieh JJ, Hakimi AA. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Urol Oncol. 2017 Aug.35(8):532.e7-532.e13. Pubmedid: 28408295. Pmcid: PMC5545055.
  • Hsieh JJ, Manley BJ, Khan N, Gao J, Carlo MI, Cheng EH. Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer. Semin Cell Dev Biol. 2017 Apr.64:98-106. Pubmedid: 27615548. Pmcid: PMC5522717.
  • Manley BJ, Hakimi AA. Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact. Curr Opin Urol. 2016 Sep.26(5):383-387. Pubmedid: 27467134. Pmcid: PMC5032025.
  • Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 2016 Nov.17(1):231. Pubmedid: 27855702. Pmcid: PMC5114739.
  • Manley B, Hakimi AA. Editorial Comment. J Urol. 2016 Nov.196(5):1370. Pubmedid: 27545335.
  • Manley BJ, Brockman JA, Raup VT, Fowler KJ, Andriole GL. Prostate MRI: a national survey of Urologist's attitudes and perceptions. Int Braz J Urol. 2016 May.42(3):464-471. Pubmedid: 27286108. Pmcid: PMC4920562.
  • Manley BJ, Hsieh JJ. Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components. Transl Cancer Res. 2016 Aug.5(Suppl 2):S160-S165. Pubmedid: 29167760. Pmcid: PMC5695716.
  • Raup VT, Potretzke AM, Manley BJ, Brockman JA, Bhayani SB. Hemorrhagic Cystitis Requiring Bladder Irrigation is Associated with Poor Mortality in Hospitalized Stem Cell Transplant Patients. Int Braz J Urol. 2015 Nov.41(6):1126-1131. Pubmedid: 26742970. Pmcid: PMC4756938.
  • Manley B, Andriole GL. Editorial comment. Urology. 2015 Feb.85(2):341-342. Pubmedid: 25623681.
  • Manley BJ, Gericke RK, Brockman JA, Robles J, Raup VT, Bhayani SB. The pitfalls of electronic health orders: development of an enhanced institutional protocol after a preventable patient death. Patient Saf Surg. 2014 Sep.8(1):39. Pubmedid: 25309624. Pmcid: PMC4193978.
  • Tomaszewski JJ, Uzzo RG, Kocher N, Li T, Manley B, Mehrazin R, Ito T, Abbosh P, Viterbo R, Chen DY, Greenberg RE, Canter D, Smaldone MC, Kutikov A. Patients with anatomically "simple" renal masses are more likely to be placed on active surveillance than those with anatomically "complex" lesions. Urol Oncol. 2014 Nov.32(8):1267-1271. Pubmedid: 24913564. Pmcid: PMC4258180.
  • Canter D, Kutikov A, Manley B, Egleston B, Simhan J, Smaldone M, Teper E, Viterbo R, Chen DY, Greenberg RE, Uzzo RG. Utility of the R.E.N.A.L. nephrometry scoring system in objectifying treatment decision-making of the enhancing renal mass. Urology. 2011 Nov.78(5):1089-1094. Pubmedid: 22054378. Pmcid: PMC3477543.
  • Kutikov A, Smaldone MC, Egleston BL, Manley BJ, Canter DJ, Simhan J, Boorjian SA, Viterbo R, Chen DY, Greenberg RE, Uzzo RG. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol. 2011 Aug.60(2):241-248. Pubmedid: 21458155. Pmcid: PMC3124570.
  • Scoll BJ, Uzzo RG, Chen DY, Boorjian SA, Kutikov A, Manley BJ, Viterbo R. Robot-assisted partial nephrectomy: a large single-institutional experience. Urology. 2010 Jun.75(6):1328-1334. Pubmedid: 20080290. Pmcid: PMC2879432.

Grants

Title: Establishing the role of aberrant splice variants as a clinical biomarker in clear cell renal cell carcinoma
Sponsor: Florida Biomedical Research Program (FBRP)
PI: Manley, B., CO-PI: Wang, L.

Patient Comments
Overall Satisfaction
4.9
★★★★★
★★★★★

244 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments